AU772026B2

AU772026B2 - Fructosamine oxidase: antagonists and inhibitors

Info

Publication number: AU772026B2
Application number: AU58871/99A
Authority: AU
Inventors: John Richard Baker; Garth James Smith Cooper
Original assignee: Protemix Corp Ltd
Current assignee: Protemix Corp Ltd
Priority date: 1998-09-25
Filing date: 1999-09-24
Publication date: 2004-04-08
Anticipated expiration: 2019-09-24
Also published as: JP2003521453A; CA2344690A1; CA2344690C; DK1115389T3; PT1115389E; ES2461195T3; AU5887199A

Description

WO 00/18392 PCT/NZ99/00161 "FRUCTOSAMINE OXIDASE: ANTAGONISTS AND INHIBITORS THE CURRENT INVENTION The present invention relates to methods of treatment, pharmaceutical compositions, dosage forms, uses of fructosamine oxidase enzyme inhibitors in medicine or for manufacturing pharmaceutical compositions, treatment regimes and related combinations, methods and products.

Diabetes mellitus is a common disorder affecting nearly 16 million Americans. See, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 20; 1183-97 (1997). Diabetic individuals are prone to complications which are a major threat to both the quality and the quantity of life. Almost half those diagnosed with diabetes before the age of 31 years die before they reach 50 years largely as a result of cardiovascular or renal complications, often with many years of crippling and debilitating disease beforehand. See, Deckert T, Poulsen J, Larsen M. Diabetologia 14:363-70 (1978). It is estimated that diabetic individuals have a 25-fold increase in the risk of blindness, a 20-fold increase in the risk of renal failure, a 20-fold increase in the risk of amputation as a result of gangrene, and a 2- to 6-fold increased risk of coronary heart disease and ischaemic brain damage. See, Klein R, Klein B, Moss S, Davis M, DeMets D. Diabetes Care 8;311-5 (1985).

Largely because of these long-term complications, the cost of diabetes in the US was estimated as $98 billion in 1997 comprising $44 billion for direct medical costs such as inpatient and outpatient care plus $54 billion for indirect costs such as lost earnings and productivity, and premature death. Medical innovations that can slow the progression of diabetes have tremendous potential to mitigate the associated clinical and cost repercussions See, American Diabetes Association, "Economic consequences of diabetes in the US in 1997," Diabetes Care 21:296-309(1998).

Elevated blood glucose levels are now regarded as causative of diabetic complications based on results of the Diabetes Complications and Control Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS). See, NEng JMed. 379:977-85 (1993) and Lancet 352:837-53 (1998). The DCCT and the WO 00/18392 PCT/NZ99/00161 -2- UKPDS have both demonstrated that the development of complications of diabetes are related with degree of hyperglycaemia and that long-term outcome may be ameliorated by rigorous treatment. For example, prognosis is dramatically improved if capillary blood glucose and glycated haemoglobin levels are maintained less than 150mg/dL and 7.0% respectively.

The mechanism of glucose toxicity in the tissues of patients with diabetes mellitus is unknown. Glucose condenses with free amino groups on structural and functional proteins to form Schiff bases which, in turn, undergo a series of transformations to yield dark-brown Maillard products. It has been proposed that diabetes complications are caused by the non-enzymatic cross-linking of proteins.

See, Cerami A, Ulrich PC, Brownlee M, US Patent 4758583 (1988). However, although increased protein cross-linking is seen in the tissues of people longstanding diabetes, the role of Maillard products as a causative factor is certainly not clear. See, Wolff SP, Jiang ZY, Hunt JV. Free Rad Biol Med 10;339-52 (1991).

Amadori-rearrangement is the most important Maillard transformation because its product, fructosamine, is the precursor of all the browning products. We I have isolated a novel extracellular enzyme which catalyses the elimination of fructosamines from glycated protein. The existence of this enzyme has not previously been recognised in the world literature. Based on its high specificity for glycated protein substrates and its use of oxygen as acceptor, the enzyme may be classified as fructosamine oxidase 1.5.3. See, Enzyme Nomenclature, Recommendations of the Nomenclature Committee of the International Union of Biochemistry, Academic Press, London pp. 19-22, (1979).

Fructosamine oxidase is a metalloenzyme with copper quinone cofactors and it belongs to the copper amine oxidase group of enzymes which have been isolated from bacteria, fungi, yeast, and mammalian sera. Products of the fructosamine oxidase catalysed reaction are free unglycated protein, a-dicarbonyl sugar, and the active oxygen species superoxide.

Increased fructosamine oxidase activity could cause many of the recognised sequelae of diabetes by degrading fructosamines bound to basement membrane proteins and generating reactive oxygen species as reaction products. For example, wn nol8392 PCT/NZ99/00161 -3superoxide anions cause an increase in intracellular calcium which modulates the activity of nitric oxide synthase. Nitric oxide is a potent vasodilator and it has been implicated in the vascular dysfunction of early diabetes. See, Ido Y, Kilo C, Williamson JR. Nephrol Dial Transplant 11 Suppl 5:72-5 (1996). Reactive oxygen species also cause a drastic dose-dependent decrease in de novo synthesis ofheparan sulfate proteoglycans leading to a reduction in anionic sites on the glomerular basement membrane and an increase in basement membrane permeability to cationic plasma proteins such as albumin. See, Kashira N, Watanabe Y, Makin H, Wallner EI, Kanwar YS. Proc Natl Acad Sci USA 89:6309-13 (1992). Increased urinary albumin clearance is a risk indicator in people with diabetes mellitus both for evolving renal disease and for early mortality mainly from coronary heart disease.

See, Mattock MB, Barnes DJ, Viberti GC, et al. Diabetes 47:1786-92 (1998).

Once natural anti-oxidant defences are exceeded, hydroxyl radicals may be generated from superoxide via a copper catalysed Haber-Weiss reaction. See, Halliwell B Gutteridge JMC "Free radicals in Biology and Medicine" Clarendon Press, Oxford pp. 136-76 (1989). Hydroxyl radicals are extremely reactive species and could cause the permanent site-specific damage to basement membrane proteins and histopathological changes that are typical of diabetic microvascular disease. See, Robbins SL, Cotran RS, Kumar V. "Pathologic basis of disease" 3 rd ed WB Saunders, pp. 991-1061. (1984).

Similarly, any prolonged increase in fructosamine oxidase activity will cause oxidative stress which could account for the excess risk of macrovascular disease and the 75% increase in mortality seen in patients with diabetes mellitus compared with non-diabetic individuals. Recent studies have convincing demonstrated that oxidative modification of low density lipoprotein (LDL) is involved in the development of atherosclerosis of coronary and peripheral arterial vessels and elevated oxidised LDL concentrations are found in subjects with diabetes mellitus.

See, Witztum JL Br Heart J 69 (Suppl):S12-S18 (1993) and Picard S, Talussot C, Serusclat A et. al. Diabetes Metabolism 22:25-30 (1996). Oxidative changes to membrane lipids and to membrane protein SH-groups may also cause aberrations in cellular calcium homeostasis and contribute to the increased incidence of cardiac WO 00/18392 PCT/NZ99/00161 -4sudden death that is typical of diabetes. See, Yucel D, Aydogdu S, Cehreli S et al.

Clin Chem 44:148-54 (1998).

SUMMARY OF THE INVENTION The existence of the fructosamine oxidase enzyme has not previously been recognised in the world literature. This is a novel enzyme. I believe that excess fructosamine oxidase activity with glycated basement membrane protein substrate plays a vital role in diabetic complications by the formation of a-dicarbonyl and reactive oxygen free radical species.

I also believe that this damage may be ameliorated by administering specific fructosamine oxidase inhibitors or antagonists selected from the groups: copper chelating agents; (ii) substrate analogues; (iii) hydrazine compounds.

As used herein (including in the claims) the terms S "copper chelating agents" means any agent which reduces body fructosamine oxidase activity by depleting body copper stores or by binding and inactivating the copper molecule at the reactive centre of the enzyme) which is capable of being administered in effective amounts by any appropriate administration route (eg. orally, by injection etc). See some examples hereafter referred to.

"substrate analogue" means any chemically modified amino acid or peptide substrate which inactivates fructosamine oxidase by binding (preferably substantially) irreversibly to the reactive centre of the enzyme) which is capable of being administered in effective amounts by any appropriate administration route (eg. orally, by injection etc). See some examples hereafter referred to.

"hydrazine compound" means any agent containing the moiety -NH-NH 2 which inactivates fructosamine oxidase by binding and inactivating the quinone molecule at the reactive centre of the enzyme) which is capable of being administered in effective amounts by any appropriate administration route (eg. orally, by injection etc). See some examples hereafter referred to.

"at least periodically" includes from a single administration to continuous 20-FEB-2004 16: 18 A J PARK 64 9 3566990 P.04 administration.

"macrovascular and microvasular damage" refers to both general types of damage but can refer to one general type of such damage provided there is a view to minimising or ameliorating the consequences of and/or likelihood of such category of damage.

"comprises" can mean "includes".

"and/or" means both "and" and "or".

"in concert with" does not necessarily mean as a result of simultaneous to administration or self administration (eg; can be serially and such serial application can be spaced, ie; triene between meals and another agent with a meal).

"triethylenetetramine dihydrochloride" or "triene" includes for the target mammalian species or for a human being any pharmaceutically acceptable fructosamine oxidase enzyme inhibiting and/or antagonising analogue or metabolite thereof (eg; an acetylated derivative) capable of administration or self administration in an amount alone, or in concert with another fructosamine oxidase enzyme inhibitor and/or antagonist (preferably not contraindicated by toxicity concerns having regard to levels required for effective inhibition and/or antagonism), of providing effective inhibition and/or antagonism.

In a first aspect the present invention consists in a method for treating a human with diabetes mellitus comprising administering to said human an effective amount of a copper-binding triene compound.

Preferably said triene is administered orally, or by a non-oral route, or Sadministration is by injection.

Preferably a long-acting release form of said triene is administered.

In another aspect the present invention consists in a method for treating a 30 human with diabetes mellitus comprising orally administering to said human a *eo 9* COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:18 A J PARK 64 9 3566990 -6copper-binding triene in an amount ranging from about 1.2 to about 2.4 grams per day.

Preferably a long-acting release form of said triene is administered.

Preferably about 600 milligrams to about 1200 milligrams of said triene is administered two times per day.

Preferably about 400 milligrams to about 800 milligrams of said triene is administered three times per day.

Preferably about 300 milligrams to about 600 milligrams of said triene is administered four times per day.

Preferably said triene is a triene salt.

Preferably said human has type 1 or type 2 diabetes.

Preferably said triene salt is a triene hydrochloride salt or a dihydrochloride salt.

Preferably said human has type 1 or type 2 diabetes.

Preferably said triene is triethylenetetramine.

Preferably said human has type 1 or type 2 diabetes.

Preferably said triethylenetetramine is a triethylenetetramine hydrochloride salt.

Preferably said triethylenetetramine hydrochloride salt is triethylenetetramine dihydrochloride.

Preferably said human has type 1 or type 2 diabetes.

In another aspect the present invention consists in a method for treating a 25 human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 9 mg/kg to about 200 mg/kg per day.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said human has type 1 or type 2 diabetes.

In a further aspect the present invention consists in a method for treating a human with diabetes mellitus comprising orally administering to said human a 4.

COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 i6:ie A J PARK 64 9 3566990 P.06 -7copper-binding triene in an amount ranging from about 11 mg/kg to about 100 mg/kg per day.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said human has type 1 or type 2 diabetes.

In another aspect the present invention consists in a method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 13 mg/kg to about 75 mg/kg per day.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said human has type 1 or type 2 diabetes.

In another aspect the present invention consists in a method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 15 mg/kg to about 50 mg/kg per day.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said human has type 1 or type 2 diabetes.

In a further aspect the present invention consists in a method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 17 mg/kg to about 35 mg/kg per day.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said human has type 1 or type 2 diabetes.

25 Preferably a long-acting release form of said triene is administered.

Preferably said triene is a triene salt.

Preferably a long-acting release form of said triene salt is administered.

Preferably said triene salt is a triene hydrochloride salt.

Preferably a long-acting release form of said triene hydrochloride salt is administered.

Preferably said triene hydrochloride salt is a dihydrochloride salt.

o COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:18 A J PARK 64 9 3566990 P.07 -8- Preferably a long-acting release form of said triene dihydrochloride salt is administered Preferably said triene is triethylenetetramine.

Preferably a long-acting release form of said triethylenetetramine is administered.

Preferably a long-acting release form of said triethylenetetramine hydrochloride salt is administered Preferably said triethylenetetramine dihydrochloride salt is triethylenetetramine dihydrochloride.

Preferably a long-acting release form of said triethylenetetramine dihydrochloride is administered.

In another aspect the present invention consists in a method for treating a human with diabetes mellitus comprising administering to said human a copperbinding triene in an amount ranging from about 120 milligrams to about 240 milligrams per day by a non-oral route of administration.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said triene is administered by infusion or by injection.

Preferably said human has type 1 or type 2 diabetes.

In a further aspect the present invention consists in a method for treating a human with diabetes mellitus comprising administering to said human a copper- 25 binding triene in an amount ranging from about 0.9 mg/kg to about 20 mg/kg per day by a non-oral route of administration.

S

Preferably said triene is administered in a single dose or in divided doses.

Preferably said triene is administered by infusion or by injection.

Preferably said human has type 1 or type 2 diabetes.

In another aspect the present invention consists in a method for treating a Shuman with diabetes mellitus comprising administering to said human a coppercoco COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:19 A J PARK 64 9 3566990 P.08 -9binding triene in an amount ranging from about 1.1 mg/kg to about 10 mg/kg per day by a non-oral route of administration.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said triene is administered by infusion or by injection.

Preferably said human has type 1 or type 2 diabetes.

In a further aspect the present invention consists in a method for treating a human with diabetes mellitus comprising administering to said human a copperbinding triene in an amount ranging from about 1.3 mg/kg to about 7.5 mg/kg per to day by a non-oral route of administration.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said triene is administered by infusion or by injection.

Preferably said human has type 1 or type 2 diabetes.

In another aspect the present invention consists in a method for treating a human with diabetes mellitus comprising administering to said human a copperbinding triene in an amount ranging from about 1.5 mg/kg to about 5.0 mg/kg per day by a non-oral route of administration.

Preferably said triene is administered in a single dose or in divided doses.

Preferably said triene is administered by infusion or by injection.

Preferably said human has type 1 or type 2 diabetes.

In another aspect the present invention consists in a method for treating a human with diabetes mellitus comprising administering to said human a copperbinding triene in an amount ranging from about 1.7 mg/kg to about 3.5 mg/kg per day by a non-oral route of administration.

25 Preferably said triene is administered in a single dose or in divided doses.

Preferably said triene is administered by infusion or by injection.

Preferably said human has type 1 or type 2 diabetes.

Preferably a long-acting release form of said triene is administered.

Preferably said triene is a triene salt.

Preferably a long-acting release form of said triene salt is administered.

Preferably said triene salt is a triene hydrochloride salt.

COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:19 A J PARK 64 9 3566990 P.09 Preferably a long-acting release form of said triene hydrochloride salt is administered.

Preferably said triene hydrochloride salt is a dihydrochloride salt.

Preferably a long-acting release form of said triene dihydrochloride salt is administered.

Preferably said triene is triethylenetetramine.

Preferably a long-acting release form of said triethylenetetramine hydrochloride salt is administered.

In still another aspect the present invention consists in a method of treating an individual with diabetes mellitus comprising administering an effective amount of a pharmaceutically acceptable copper chelator.

Preferably in the method macrovascular and microvascular damage is lessened.

25 Preferably the amount administered to said individual decreases the amount l of copper in the body.

Preferably said amount affects copper metabolism as a result of administration of at least one copper chelator to said individual.

Preferably said copper chelator is a triene.

'30 In further aspect the present invention consists in a method for treating an individual with diabetes mellitus comprising administering to said individual an COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:19 A J PARK 64 9 3566990 effective amount of a pharmaceutically acceptable amount of a copper chelator and an ACE inhibitor.

Preferably said ACE inhibitor is selected from the group consisting of captropril, lisinopril, and enalapril.

Preferably said copper chelator is a triene.

Preferably macrovascular and microvascular damage is lessened.

Reference is drawn to my PCT Application filed simultaneously herewith (claiming priority of New Zealand Patent Specification No. 332085 filed to September 1998), the full content of which is hereby included by way of reference.

It discloses methods of monitoring fructosamine oxidase inhibition and/or antagonism of patients, screening and/or determine patients to determine patients at risk to vascular (particularly microvascular) damage and identifying those individuals who will benefit by treatment with fructosamine oxidase inhibitors is and/or antagonists, methods of determining fructosamine oxidase levels in a mammal, methods of determining blood plasma fructosamine oxidase levels in a diabetic individual or a suspected individual, methods of assaying blood serum or blood plasma in vitro for fructosamine oxidase, methods of identifying or testing candidate substances and to related methods and procedures.

Preferably the measurement conducted in vitro is of the superoxide reaction product (or any other oxygen free radical product) of fructosamine oxidase).

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows a detailed reaction mechanism for the formation of 25 fructosamine and Maillard products from glucose and protein. Fructosamine oxidase eo degrades fructosamine by a two-step reaction with initial release of an -dicarbonyl sugar and subsequent oxidation of the enzyme/protein complex to release free unglycated protein. The reduced copper cofactor is oxidised in vivo by molecular oxygen and the oxidation product is superoxide.

30 Figure 2 shows absorbance spectra of the fructosamine oxidase enzymes extracted from pooled human sera and from the microbial organism, Enterbacter S. aerogenes COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 WO nnlF/1392 PCT/NZ99/00161 11 Figure 3 shows spectra ofp-nitrophenylhydrazine (NPH) adduct of the Enterbacter aerogenes enzyme and a red absorbance shift when the NPHenzyme adduct is diluted in 2M KOH.

Figure 4 shows survival curve for non-treated STZ-diabetic rats compared with diabetic animals treated with fructosamine oxidase inhibitors.

Figure 5 shows monthly growth of treated and untreated STZ-diabetic rats compared with non-diabetic animals.

DETAILED DESCRIPTION OF THE INVENTION Extraction of holoenzyme Fructosamine oxidase in blood plasma is largely found as an enzyme-substrate conjugate, bound to peptides and proteins (Fig To obtain a maximal yield of active holenzyme, it is necessary to make the pH of the media alkaline preferably with phosphate buffer, to add sulphydryl reagents, and to incubate the mixture with pro-oxidant so that glycated species are released. Most effective activation is found with cupric salts.

Fructosamine oxidase holenzyme is separated from inactive apoenzyme by affinity adsorption chromatography. A suitable glycated affinity support is prepared from alkylamine beads or beaded cross-linked agarose with amino terminal residues attached by 6-10 atom spacer arms (available from PierceTM, Bio-RadTM, PharmaciaTM). Affinity support is glycated by incubating with 400mM potassium phosphate buffer pH 7.4 containing 50mM glucose and 0.01% sodium azide at 37 °C for 7 days. Holoenzyme binds tightly to glycated amino residues and residual copper is readily removed by washing with water. Active holoenzyme is eluted with 800mM NaCl in 50mM sodium acetate buffer pH 4.8. Active fractions are pooled and protein is precipitated with 50% cold acetone solvent. The protein pellet is reconstituted with a minimal volume of water or physiological saline and lyophilised for long term storage.

Extraction of 35mL pooled diabetic and non-diabetic human sera yielded a clear colourless preparation with absorbance peaks at 196nm 264nm typical of the absorbance spectra of fructosamine oxidase (Fig A fructosamine oxidase enzyme WO 00/18392 PCT/NZ99/00161 -12from Enterobacter aerogenes showing absorbance peaks at 196nm 255nm is included for comparison. Enzyme activity and relative activity is as follows.

TABLE 1.

Sample Protein Cytochrome c activity* Sp activityt (pg/mL) (UIL) (U/g) human 32.9 4.58 139.4 E aerogenes 541.5 66.32 115.11 Enzyme extract was preincubated in 0.05M TES buffer pH 7.4 containing ImM DMF substrate at 37 °C for 5 minutes. Enzyme activity was measured with 10M ferricytochrome c. The reaction was started with 50pM fructosamine substrate as g-BSA and AA550nm was determined over 5 minutes.

f Protein concentration determined from A210nm-A220 m compared with BSA standards.

(ii) Cofactor identification The p-nitrophenylhydrazine (NPH) adduct of Enterbacter aerogenes enzyme with Aax 399nm was obtained as described previously. See, Palcic MM, Janes SM.

Meth Enzymol 258:34-8 (1995). A red absorbance shift to Amax 438nm was observed when the NPH-enzyme adduct was diluted in 2M KOH. Such an absorbance shift is typical of the quinone cofactors of copper amine oxidase.

EXAMPLE 1: Identifying fructosamine oxidase inhibitors The purpose of this example is to demonstrate how the fructosamine oxidase assay, the subject of a simultaneously filed PCT International patent specification NZ 332085, may be used in identifying and grading candidate fructosamine oxidase inhibitors. This approach takes into account the activity of the drug in a human plasma matrix in vitro. Enzyme inhibitors find wide application in clinical medicine as treatments for a range of metabolic disorders. For example, angiotensin converting enzyme inhibitors have been used in the treatment of hypertension. See, Harris EE, Patchett AA, Tristram EW, Wyvratt MJ. Aminoacid derivatives as antihypertensives. US Patent 4374829 (1983). Similarly, 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase enzyme inhibitors have been used in the treatment of hypercholesterolaemia. See, Hoffman WF, Smith RL, Lee WO 00/18392 PCT/NZ99/00161 -13- TJ. Novel HMG-CoA reductase inhibitors. US Patent 4866090 (1989). Fructosamine oxidase inhibitors may be selected from those substances which bind and block the quinone co-factor (hydrazine compounds), the copper co-factor (copper chelators), or which mimic the normal substrate of the enzyme (substrate analogue).

Method: Potential fructosamine oxidase inhibitors were tested on human serum or plasma (individually and in combination) using the method of assayingfructosamine oxidase activity described in detail in a New Zealand Patent Specification No.

332085. Irreversible enzyme inhibition is characterised by a progressive decrease in activity with time ultimately reaching complete inhibition even with very dilute inhibitor concentrations provided that the inhibitor is in excess of the amount of enzyme present.

Results: The relative activity of a selection of hydrazine, copper chelator, and substrate analogue Fructosamine oxidase inhibitors are shown in TABLE 2. In some instances, there was a degree of overlap between classes i.e. some hydrazine compounds are also copper chelators. To clarify this point, copper chelating potential for some compounds is indicated The effectiveness of the inhibitor is expressed not by an equilibrium constant but by a velocity constant which determines the fraction of the enzyme inhibited in a given period of time by a certain concentration of inhibitor. The specificity of the inhibitor for the active centre of the enzyme is indicated by the concentration of inhibitor CAUSING 50% inactivation of the enzyme (IC, 5 PCT/NZ99/00161 WO 00/h18392PCNZ/OI6 14 TABLE 2 Inhibitor: Hydrazine compounds K(min")' 03 aminoguanidine 231 .2pM 0.0067* semicarbazide 45.1 pM 0.0276* benserazide 13.6pM 0.0095* oxalic dihydrazide 1.59pM 0.0542 hydralazine 1 .52pM 0.0029..

phenyihydrazine 0.8l PM 0.1160 carbidopa 0.5OpM 0.1496 diaminoguanidine 0.36pM 0.1340 Inhibitor: Substrate analogues lisinopril 216.9pM 0.0174 enalapril 3.95pM 0.0326..

captopril 1.78pM 0.0259 acetylpenicillamine 1 .O6pM 0.0811 acetylcysteine 0.83pM 0.1677 Inhibitor: Copper chelators desferrioxamine 40.6pM 0.0109* EDTA 15.7pM 0.0755* Sodium azide 9.48pM 0.0004 Potassium cyanide 6.36pM 0.0116 triene 5.4OpM 0.0196 o-phenanthroline 4.25pM 0.0385 histidine 2.29pM 0.0554 Inhibitor: Combined agents acetylcysteine hydralazine 0.57pM 0.1654 acetylcysteine diaminoguanidine 1.O7gjM 0.0795 acetylcysteine histidine 1.11 PM 0.0722 acetylcysteine carbidopa 0.27pM 0.2000 1 fresh human sera was incubated with 0-1 ,OOOpM inhibitor in 0.05M TES buffer pH 7.4 at 37 *C for minutes. Enzyme activity was measured with 10pM ferricytochrome c. The reaction was started with fructosamine substrate as g-BSA and AA550nm was determined over 5 minutes.

2 rate constants were calculated from the reaction of fructosamine oxidase either with 1 .OpM inhibitor or with 10.OpM inhibitor 3 copper chelating potential was determined from ability of agent to remove copper under dialysis from copper-saturated BSA substrate.

WO 00/18392 PCT/NZ99/00161

CONCLUSION:

1. Irreversible inhibition offructosamine oxidase is feasible.

2. Inhibitors may be broadly categorised in three classes of compound: hydrazines; substrate analogues; copper chelators.

3. Fructosamine oxidase activity in human blood plasma may be eliminated by micromolar concentrations of inhibitors.

4. Many of the active inhibitors are drugs which have already been administered as medicines in humans to treat other disorders (not diabetes).

EXAMPLE 2: Clinical Utility offructosamine oxidase inhibition: First Preclinical study The purpose of this example is to demonstrate how the clinical usefulness of candidatefructosamine oxidase inhibitors may be assessed using a standard animal model of diabetes mellitus, the streptozocin-diabetic rat (STZ rat). This approach takes into account drug bioavailability, the activity of the drug and its metabolites, and any drug adverse effects or toxicity factors.

Method: 48 WISTAR rats aged 6-8 weeks weighing 200-300g were randomized: Group 1 Non-diabetic control Group 2 Diabetic control Group 3 Diabetic treated with hydralazine Group 4 Diabetic treated with EDTA Group 5 Diabetic treated with hydralazine acetylcysteine Group 6 Diabetic treated with acetylcysteine.

Streptozotocin (60mg per kg) was administered into a lateral tail vein. Nondiabetic controls received a sham injection of buffer. Diabetes was confirmed by venous blood glucose measurement >15mmol/L after 1 week diabetic animals were treated with subcutaneous injections of ultralente insulin (4U/injection) days per week to maintain body growth. Medications were administered 50mg/L in \Oi\ 0/11 Q9' PCT/iN700/nnil 1 16 the drinking water over an 8 month period. Timed urine collects and venous plasma samples were obtained at monthly intervals.

Results: Blood glucose control: Rate of conversion to diabetes with intravenous STZ administration was Intravenous STZ induced a severe form of insulindependent diabetes which was sustained over the entire 8 month duration of the study. Despite insulin replacement therapy, glycaemia control was poor as evidenced by mean SD glucose (week 4) and HbAc (week 32) levels in TABLE 3.

TABLE 3.

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Glucose (mmol/L) 9.1±1.5 30.1±9.7 35.7±9.5 39.0±6.4 30.4±8.8 37.8±5.2 HbA,c 3.92±0.11 10.85±0.05 8.65±1.18 9.30±0.63 8.72±0.55 9.47±1.23 Survival: Mortality rate amongst untreated STZ rats was extremely high.

Survival was improved significantly by the administration offructosamine oxidase inhibitors (TABLE 4).

TABLE 4.

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Survivors at week 32 8 2 6 5 8 7 Significance* ns ns P <0.025 P <0.05 S Chi-square test compared with untreated STZ rats (Group 2) The survival curve for STZ rats compared with non-diabetic controls is shown in FIGURE 4. Death was presumed secondary to a cardiovascular event. In general, renal function remained normal.

Weight gain: There was a progressive weight gain amongst non-diabetic controls over the 32 weeks of the study which was abolished in the STZ diabetic animals. At the end of the 32 week study period, mean weight change amongst vN nni/ Q1l0 PCT/NT99qo/nl 61 -17surviving study animals was: Group 1, Group 2, Group 3, Group 4, Group 5, Group 6, (FIGURE Compared with untreated diabetic controls, fructosamine oxidase inhibitors caused an improvement in weight gain roughly in proportion to the activity of the inhibitor (TABLE 2) i.e. acetylcysteine/hydralazine EDTA acetylcysteine hydralazine.

Clinical pharmacokinetics: Hydralazine The bioavailability of hydralazine in man after oral administration is 26-55%. However, only 2.0-3.6% of the drug is excreted in the urine unchanged over 24 hours after oral administration. Most of the drug is recovered as an inactive acetylated product. See, Talseth T, Eur J Clin Pharmacol 10:395-401 (1976) and Talseth T, Clin Pharmacol Ther 21:715-20 (1977). This could account for the reduced efficacy of hydralazine as a fructosamine oxidase inhibitor in the current study. Furthermore, drug doses administered to each STZ rat were calculated as 12.5mg hydralazine/day or based on an average consumption 250mL water per day and assuming a mean body mass 350g. This rat dose far exceeds the maximum recommended human dose of 200mg hydralazine per day (3mg/kg assuming a mean body mass EDTA The bioavailability of EDTA after oral administration is very low (less than because of poor absorption from the gut limiting its usefulness in humans to parenteral administration or irrigation techniques. See, Wynn JE et al Toxicol Appl Pharmacol 16:807-17 (1970).

Acetylcysteine Acetylcysteine is rapidly absorbed from the gut with an bioavailability in man varying between 6 and 10%. See, Borgstrom L et al Eur J Clin Pharmacol 31:217-22 (1986). However, the drug is rapidly degraded in the liver by elimination of the acetyl moiety. See, Holdiness MR. Clin Pharmacokinet 20:123-34 (1991). Induction of liver enzymes could account for the progressive loss of drug efficacy seen after week 12 in the current study.

wn 00/18392 PCT/NZ99/00161 -18-

CONCLUSION:

Streptozocin induces a severe form of insulin dependent diabetes in the rat with a high morbidity and mortality.

6. Survival of STZ rats was enhanced by treating with fructosamine oxidase inhibitors in proportion to their activity in an in vitro assay.

7. Weight gain of STZ rats was enhanced by treating with fructosamine oxidase inhibitors.

8. There was benefit in co-administering acetylcysteine and hydralazine suggesting a synergy effect between classes offructosamine oxidase inhibitors.

9. Based on these in vivo studies in the rat, the efficacy of a candidate of fructosamine oxidase inhibitor in a human is likely to be influenced by bioavailablity of the drug, degradation of the active compound in vivo, and maximum oral tolerated dose of the drug.

EXAMPLE 3: Clinical utility offructosamine oxidase inhibition: Second Preclinical study The purpose of this example is to demonstrate how the clinical usefulness of candidatefructosamine oxidase inhibitors, alone and in combination, may be assessed using a standard animal model of diabetes mellitus, the streptozocindiabetic rat (STZ rat). This approach takes into account drug bioavailability, the activity of the drugs and their metabolites, interactions between drugs, and any drug adverse effects or toxicity factors.

Method: Wistar rats weighing 200-300g and aged of 6-8 weeks were randomized: Group 1 Non-diabetic control Group 2 Diabetic control Group 3 Diabetic treated with captopril (substrate analogue) Group 4 Diabetic treated with carbidopa (hydrazine) Group 5 Diabetic treated with triene (copper chelator) wN nnI 8397 PT/N 799q/nn 161 -19 Group 6 Diabetic treated with captopril triene.

Group 7 Diabetic treated with captopril carbidopa Group 8 Diabetic treated with triene cardidopa.

Diabetes was induced by administering streptozotocin (60mg per kg) by intraperitoneal injection. Non-diabetic controls received a sham injection of buffer.

Diabetes was confirmed by venous blood glucose measurement >15mmol/L after 1 week diabetic animals were treated with subcutaneous injections ofultralente insulin (4U/injection) 3 days per week to maintain body growth. Medications were administered 50mg/L in the drinking water over an 6 month period. Timed urine collects and venous plasma samples were obtained at monthly intervals. Animals were sacrificed and subjected to post-mortem at the end of the study.

Results: Blood glucose control: Rate of conversion to diabetes with intraperitoneal STZ administration was Poor glycaemic control was sustained over the 6 month duration of the study as evidenced by mean SD HbA,, (week 4, 12, 24) levels (TABLE TABLE HbA,, Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Week 4 4.1±0.1 8.3±0.9 8.5±0.9 9.0±1.0 8.0±1.0 9.0±5.2 9.1±1.5 9.1±1.5 Week 12 4.1±0.1 9.2±0.6 9.2±1.1 9.6±0.7 8.8±0.9 9.5±0.8 9.5±1.0 9.3±0.9 Week 24 3.7±0.1 9.4±1.3 9.6±1.3 9.9±1.1 9.0±1.4 9.5±1.3 9.8±1.2 9.1±1.2 Survival: Compared with intravenous administration of STZ, intraperitoneal adminstration of STZ induced a less severe form of diabetes with lesser mortaility rate. At the end of the 24 week study period, mortality rate amongst study animals was: Group 1, Group 2, 14.3%, Group 3, Group 4, Group 5, 0%; Group 6, 12.5%, Group 7, Group 6, There was no significant difference between groups because of the low frequency of events.

Weight gain: STZ diabetes causes a profound weight loss in diabetic rats compared with non-diabetic controls. Mean weight gain of study animals from the

A

W nnn/llQ9o PCT/N7.9qq/lnn1161 beginning to the end of the 24 week period are indicated in TABLE 6.

TABLE 6.

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 Mean SEM 342.8 54.4 60.7 33.7 123.6 56.1 55.1 75.8 weight gain 13.7 12.5 20.7 20.4 20.5 21.3 17.1 25.4 P* ns ns ns 0.0138 ns ns ns Student's t test compared with untreated STZ rats (Group 2) In terms of general well-being, triene (Group 5) appears more effective than captopril (Group 3) and carbidopa (Group The usefulness of triene was reduced when the drug was co-administered with captopril (Group 6) or carbidopa (Group 8).

There is no evidence of synergy between classes offructosamine oxidase inhibitors.

Cataract formation Cataract is a recognised long-term complication of poorly controlled diabetes. Gross cataract formation in STZ rats compared with diabetic control animals by the end of the study at week 24 is shown (TABLE 7).

TABLE 7.

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 No with 8 2 2(25%) 2(28%) 5(62%) 1(12%) cataract P ns ns 0.10 ns ns ns S Chi-square test compared with diabetic control rats (Group 2) Although not significant at the P 0.05 level, triene appears more effective than captopril and carbidopa in inhibiting gross cataract formation. There is no evidence of synergy between classes offructosamine oxidase inhibitors.

Diabetic cardiomyopathy Cardiomyopathy is a recognised long-term complication of poorly controlled diabetes. Macroscopically, hearts of STZ rats were dilated with thinning of the ventricular wall. Sections stained with haematoxylin and eosin and Masson's Trichrome showed focal pallor with a loss of normal wn Nln/1 Rt PCT/N7 Z9/n0161 -21architecture in the myocardium of both ventricles that began at the sub-endocardial and sub-epicardial regions and spread to encompass the whole ventricular wall in severely affected animals. There was also marked infiltration by fibrous connective tissue between myocytes and increased fibrous connective tissue in the walls of intramural arteries. These appearance are consistent with dilated cardiomyopathy.

Gross myocardial fibrosis in STZ rats compared with non-diabetic control animals by the end of the study at week 24 is shown (TABLE 8) TABLE 8.

Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 Group 7 Group 8 No rats 0 10 6 2 0 6 8 7 with severe (100%) (87%) fibrosis P ns ns 0.005 ns <0.005 <0.05 S Chi-square test compared with diabetic control rats (Group 2) Triene appears highly effective in inhibiting the development of diabetic cardiomyopathy.. There is no evidence of synergy between classes offructosamine oxidase inhibitors.

Clinical pharmacokinetics: Triene The bioavailability of triene is less than 10%. Most of the unchanged drug is cleared in the urine within the first 6 hours of oral dosing mainly as an acetyl derivative indicating that a three or four times daily drug regimen or a sustained release preparation will be required. See, Kodama H et al Life Sci 61:899-907 (1997). In addition, plasma levels in non-fasted rats are significantly lower than those observed in fasted animals and the uptake of triene from the intestinal brush border is competitively inhibited by other amine compounds. See, Tanabe R et al JPharm Pharmacol 48:517-21 (1996). This implies that triene is best administered in the fasting state. Interference in the absorption of drug from the intestinal brush border could account for Jr f~^1 rf/o~nr' orPT/%rnnnL £1 w" UU/ /I 3y. 22 discrepancies between triene treatment groups (Groups 5, 6, Finally, in the current study, each STZ rat consumed approximately 250mL water per day (12.5mg triene/rat/day). Assuming a mean body mass 3 50g, this dose of triene equates to 35mg/kg. The dose of triene previously used in treating humans with another condition (not diabetes) ranges 1.2-2.4g (17-35mg/kg assuming a mean body mass 70kg). See, Walshe JM Lancet 8273:643-7 (1982). This implies that humans may be safely treated with comparable doses of trienes to those administered to rats in the current study to thereby elicit the fructosamine oxidase inhibition and/or antagonism advantages in a diabetic patient referred to herein.

Captopril The bioavailability of captopril is approximately 65% after an oral dose. However, the drug is almost completely bound in vivo to albumin and other plasma proteins, and forms inactive mixed disulphides with endogenous thiols so that plasma levels of active drug may be very low. The elimination half life of unchanged captopril is approximately 2 hours. See, Duchin KL et al Clin Pharmacokinet 14:241-59 (1988). These observations might explain the reduced efficacy of captopril in the STZ rat compared with in vitro studies.

Furthermore, each STZ rat consumed approximately 12.5mg captopril/day which equates to 35mg/kg assuming a mean body mass 350g. This dose far exceeds the maximum recommended human dose of 150mg captopril per day (2mg/kg assuming a mean body mass Carbidopa In a study of beagle dogs, the oral absorption of carbidopa was almost complete and the absolute bioavailability was 88%. The biological halflife was 5 hours. See, Obach R et al JPharm Pharmacol 36:415-6 (1984).

However, carbidopa is an unstable compound and it degrades naturally in a short period. Solutions left to stand exposed to light at room temperature will undergo 50% oxidative degradation in 24 hours. See, Pappert EJ et al Movement Disorders 12:608-23 (1997). Reduced bioavailability due to oxidative degradation of the active drug both prior to its consumption and postingestion in the rat could explain (in part) the reduced efficacy of carbidopa in the current study. Finally, each STZ rat consumed approximately 12.5mg l/ nn/ll1lQ PCT/NZ9/nOmn1 S- 23 carbidopa/day which equates to 35mg/kg assuming a mean body mass 350g.

This dose far exceeds the maximum recommended human dose of 200mg carbidopa per day (3mg/kg assuming a mean body mass

CONCLUSION:

Intraperitoneal streptozocin is associated with a lower mortality rate than intravenous streptozocin in the rat.

11. Weight gain was enhanced in STZ rats treated with the copper chelator, triene.

Captopril and carbidopa were ineffective.

12. Cataract development may be inhibited by triene. Efficacy of triene is diminished when the drug is co-administered with either captopril or carbidopa.

13. The development of diabetic cardiomyopathy was prevented by treatment with triene. Efficacy of triene is diminished when the drug is co-administered with either captopril or carbidopa.

14. Oral doses of triene which inhibit the development of complications in the rat (cataract, cardiomyopathy, and early death) are equivalent on a body mass basis to doses of triene which have previously been used to treat human beings with another condition (not diabetes).

15. When administered to humans on a three or four times daily basis or as a sustained release preparation in previously tolerated doses 1.2-2.4g/day, triene may provide an effective means of treating the long-term complications of diabetes mellitus.

EXAMPLE 4: Clinical Utility offructosamine oxidase inhibition: double-blind, placebo-controlled clinical trial The purpose of this example is to demonstrate how the clinical usefulness of candidate fructosamine oxidase inhibitors will be assessed in diabetic human subjects. A detailed protocol based on this proposal has been approved by the Auckland Regional Ethics Committee. This approach takes into account drug bioavailability, the activity of the drugs and their metabolites, interactions between WO nn1/n1a2 PCT/N709/fool61 -24 drugs, any drug adverse effects or toxicity factors and the "scale-up" factor from rat to human treatment..

Objective: A pilot study to determine whether triene will reduce the rate of progression of renal disease and associated microvascular complications in patients with diabetic nephropathy due to NIDDM.

Patient population: 60 men and women aged between 40 years and 70 years of age with poor blood glucose control and diabetic nephropathy due to NIDDM.

Study design and duration: Randomised double-blind, placebo-controlled study design consisting of five periods: screening period (detecting possible candidates who meet study criteria); enrolment period (securing informed consent baseline measurements); run-in period (trial of acceptability of study protocols study medication); maintenance period (treatment with drug/placebo, monitoring efficacy/safety); follow-up period (detect any untoward effect when medication is disconitinued).

Blinded therapy (triene 400mg or placebo) will be administered three time daily /2 hour before meals in addition to current antihypertensive and hypoglycaemic therapies. The study will terminate when all patients are randomised and have been in the study (maintenance period) for a minimum of 6 months. All randomised patients who discontinue study drug for any reason other than death will be followed for the entire duration of the study; patients who undergo renal transplantation or dialysis will be followed for vital status only.

Outcomes Efficacy: The primary outcome measure will consist of rate of decline in renal function as measured by glomerular filtration rate (creatinine clearance).

The secondary outcome measures to be evaluated are development of diabetic retinopathy, diabetic peripheral neuropathy, and diabetic autonomic neuropathy.

Safety: Safety parameters evaluated will be adverse events and clinical laboratory

I

\Odl 0n/I1 Q0 PCT/NZ7.99/nl61 abnormalities which will be assessed at time points by medical history, physical examination, and laboratory analyses and compared between groups.

Statistical considerations: The sample size estimate for this trial is determined for the primary hypothesis that the projected rate of decay of creatinine clearance (lmL.min-l) in NIDDM patients with diabetic nephropathy (creatinine clearance <90 mL.min-1) will be reduced by treating with triene. The study is powered to detect a 6mL.min-1 change in creatinine clearance over 6 months with four 2-monthly readings 0, 2, 4, 6 months) assuming a 10% rate of loss to follow-up at the 5% significance level.

CONCLUSION:

16. The efficacy of triene as a treatment of microvascular complications in patients with NIDDM will be confirmed.

17. The safety of long-term administration of triene in patients with poor blood glucose control and diabetic nephropathy due to NIDDM will be confirmed.

18. It also provides a means to determine the clinical usefulness of alternative fructosamine oxidase inhibitors such as the copper chelating compounds Dpenicillamine, sar, and diamsar (ie; triene could be used in place of placebo in ensuing clinical trials).

Claims

20-FEB-2004 16:20 A J PARK 64 9 3566990 P.11 -26- WHAT IS CLAIMED IS: 1. A method for treating a human with diabetes mellitus comprising administering to said human an effective amount of a copper-binding triene compound. 2. The method of claim 1 wherein said triene is administered orally. 3. The method of claim 1 wherein said triene is administered by a non-oral route. 4. The method of claim 3 wherein said administration is by injection. The method of claim 1 wherein a long-acting release form of said triene is administered. 6. The method of claim 2 wherein a long-acting release form of said triene is administered. 7. The method of claim 3 wherein a long-acting release form of said triene is administered. 8. A method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 1.2 to about 2.4 grams per day. 9. The method of claim 8 wherein a long-acting release form of said triene is administered. The method of claim 5 wherein about 600 milligrams to about 1200 milligrams of said triene is administered two times per day. 11. The method of claim 5 wherein about 400 milligrams to about 800 milligrams of said triene is administered three times per day. 12. The method of claim 5 wherein about 300 milligrams to about 600 *milligrams of said triene is administered four times per day. 30 13. The method of any of claims 1-11 or 12 wherein said triene is a triene salt. 14. The method of claim 13 wherein said human has type 1 diabetes. The method of claim 13 wherein said human has type 2 diabetes. 0 00 0 COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:20 A J PARK 64 9 3566990 P.12 -27- 16. The method of claim 13 wherein said triene salt is a triene hydrochloride salt. 17. The method of claim 13 wherein said triene salt is a dihydrochloride salt. 18. The method of either of claims 16 or 17 wherein said human has type 1 diabetes. 19. The method of either of claims 16 or 17 wherein said human has type 2 diabetes. The method of any of claims 1-11 or 12 wherein said triene is triethylenetetramine.
21. The method of claim 20 wherein said human has type 1 diabetes.
22. The method of claim 20 wherein said human has type 2 diabetes.
23. The method of claim 20 wherein said triethylenetetramine is a triethylenetetramine hydrochloride salt.
24. The method of claim 23 wherein said triethylenetetramine hydrochloride salt is triethylenetetramine dihydrochloride.
25. The method of either of claims 23 or 24 wherein said human has type 1 diabetes.
26. The method of either of claims 23 or 24 wherein said human has type 2 diabetes.
27. A method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 9 mg/kg to about 200 mg/kg per day.
28. The method of claim 27 wherein said triene is administered in a single dose or in divided doses. S: 29. The method of claim 28 wherein said human has type 1 diabetes.
30. The method of claim 28 wherein said human has type 2 diabetes.
31. A method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 11 mg/kg to about 100 mg/kg per day. 0 *000 *00o COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:20 A J PARK 64 9 3566990 P.13 -28-
32. The method of claim 31 wherein said triene is administered in a single dose or in divided doses.
33. The method of claim 32 wherein said human has type 1 diabetes.
34. The method of claim 32 wherein said human has type 2 diabetes. A method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 13 mg/kg to about 75 mg/kg per day.
36- The method of claim 35 wherein said triene is administered in a single dose or in divided doses.
37. The method of claim 36 wherein said human has type 1 diabetes.
38. The method of claim 36 wherein said human has type 2 diabetes.
39. A method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from about 15 mg/kg to about 50 mg/kg per day. The method of claim 39 wherein said triene is administered in a single dose or in divided doses.
41. The method of claim 40 wherein said human has type 1 diabetes.
42. The method of claim 40 wherein said human has type 2 diabetes.
43. A method for treating a human with diabetes mellitus comprising orally administering to said human a copper-binding triene in an amount ranging from 25 about 17 mg/kg to about 35 mg/kg per day.
44. The method of claim 43 wherein said triene is administered in a single dose or in divided doses. The method of claim 44 wherein said human has type I diabetes.
46. The method of claim 44 wherein said human has type 2 diabetes.
47. The method of any of claims 27-45 or 46 wherein a long-acting release form of said triene is administered.
48. The method of any of claims 27-45 or 46 wherein said triene is a triene 9999 salt. 9 9 9 99* COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:21 A J PARK 64 9 3566990 P.14 -29-
49. The method of claim 48 wherein a long-acting release form of said triene salt is administered. The method of claim 48 wherein said triene salt is a triene hydrochloride salt.
51. The method of claim 48 wherein a long-acting release form of said triene hydrochloride salt is administered.
52. The method of claim 50 wherein said triene hydrochloride salt is a dihydrochloride salt.
53. The method of claim 52 wherein a long-acting release form of said triene dihydrochloride salt is administered
54. The method of any of claims 27-45 or 46 wherein said triene is triethylenetetramine. The method of claim 54 wherein a long-acting release form of said triethylenetetramine is administered.
56. The method of claim 54 wherein said triethylenetetramine is a triethylenetetramine hydrochloride salt.
57. The method of claim 56 wherein a long-acting release form of said triethylenetetramine hydrochloride salt is administered
58. The method of claim 56 wherein said triethylenetetramine dihydrochloride salt is triethylenetetramine dihydrochloride. 25 59. The method of claim 58 wherein a long-acting release form of said tricthylenetetramine dihydrochloride is administered.
60. A method for treating a human with diabetes mellitus comprising administering to said human a copper-binding triene in an amount ranging from about 120 milligrams to about 240 milligrams per day by a non-oral route of 30 administration.
61. The method of claim 60 wherein said triene is administered in a single dose or in divided doses.
62. The method of claim 60 wherein said triene is administered by infusion. COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:21 A J PARK 64 9 3566990
63. The method of claim 60 wherein said triene is administered by injection.
64. The method of claim 60 wherein said human has type I diabetes. The method of claim 60 wherein said human has type 2 diabetes.
66. A method for treating a human with diabetes mellitus comprising administering to said human a copper-binding triene in an amount ranging from about 0.9 mg/kg to about 20 mg/kg per day by a non-oral route of administration.
67. The method of claim 66 wherein said triene is administered in a single dose or in divided doses.
68. The method of claim 66 wherein said triene is administered by infusion.
69. The method of claim 66 wherein said triene is administered by injection.
70. The method of claim 66 wherein said human has type I diabetes.
71. The method of claim 66 wherein said human has type 2 diabetes.
72. A method for treating a human with diabetes mellitus comprising administering to said human a copper-binding triene in an amount ranging from about 1.1 mg/kg to about 10 mg/kg per day by a non-oral route of administration.
73. The method of claim 72 wherein said triene is administered in a single dose or in divided doses.
74. The method of claim 72 wherein said triene is administered by infusion. The method of claim 72 wherein said triene is administered by injection.
76. The method of claim 72 wherein said human has type 1 diabetes.
77. The method of claim 72 wherein said human has type 2 diabetes.
78. A method for treating a human with diabetes mellitus comprising administering to said human a copper-binding triene in an amount ranging from about 1.3 mg/kg to about 7.5 mg/kg per day by a non-oral route of administration.
79. The method of claim 78 wherein said triene is administered in a single dose or in divided doses.
80. The method of claim 78 wherein said triene is administered by infusion.
81. The method of claim 78 wherein said triene is administered by injection.
82. The method of claim 78 wherein said human has type 1 diabetes. COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:21 A J PARK 64 9 3566990 P.16 -31-
83. The method of claim 78 wherein said human has type 2 diabetes.
84. A method for treating a human with diabetes mellitus comprising administering to said human a copper-binding triene in an amount ranging from about 1.5 mg/kg to about 5.0 mg/kg per day by a non-oral route of administration. The method of claim 84 wherein said triene is administered in a single dose or in divided doses.
86. The method of claim 84 wherein said triene is administered by infusion.
87. The method of claim 84 wherein said triene is administered by injection.
88. The method of claim 84 wherein said human has type 1 diabetes.
89. The method of claim 84 wherein said human has type 2 diabetes.
90. A method for treating a human with diabetes mellitus comprising administering to said human a copper-binding triene in an amount ranging from about 1.7 mg/kg to about 3.5 mg/kg per day by a non-oral route of administration.
91. The method of claim 90 wherein said triene is administered in a single dose or in divided doses.
92. The method of claim 90 wherein said triene is administered by infusion.
93. The method of claim 90 wherein said triene is administered by injection.
94. The method of claim 90 wherein said human has type 1 diabetes. The method of claim 90 wherein said human has type 2 diabetes.
96. The method of any of claims 60-94 or 95 wherein a long-acting release 25 form of said triene is administered.
97. The method of any of claims 60-94 or 95 wherein said triene is a triene 9. Ssalt.
98. The method of claim 97 wherein a long-acting release form of said triene salt is administered.
99. The method of claim 97 wherein said triene salt is a triene hydrochloride salt.
100. The method of claim 99 wherein a long-acting release form of said triene hydrochloride salt is administered. *.i 9 99* COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:21 A J PRRK 64 9 3566990 P.17 -32-
101. The method of claim 99 wherein said triene hydrochloride salt is a dihydrochloride salt.
102. The method of claim 101 wherein a long-acting release form of said triene dihydrochloride salt is administered.
103. The method of any of claims 60-94 or 95 wherein said triene is triethylenetetramine.
104. The method of claim 103 wherein a long-acting release form of said triethylenetetramine is administered.
105. The method of claim 103 wherein said triethylenetetramine is a triethylenetetramine hydrochloride salt.
106. The method of claim 103 wherein a long-acting release form of said triethylenetetramine hydrochloride salt is administered.
107. The method of claim 105 wherein said triethylenetetramine hydrochloride salt is triethylenetetramine dihydrochloride.
108. The method of claim 107 wherein a long-acting release form of said triethylenetetramine dihydrochloride is administered.
109. A method of treating an individual with diabetes mellitus comprising administering an effective amount of a pharmaceutically acceptable copper chelator.
110. The method according to claim 109 wherein macrovascular and microvascular damage is lessened. 1. The method according to claim 109 wherein the amount administered to said individual decreases the amount of copper in the body.
112. The method according to claim 109 wherein the said amount affects 30 copper metabolism as a result of administration of at least one copper chelator to said individual.
113. The method according to any of claims 109-112 wherein said copper chelator is a triene. 9. 9 COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20 20-FEB-2004 16:22 A J PARK 64 9 3566990 P.18 -33-
114. A method for treating an individual with diabetes mellitus comprising administering to said individual an effective amount of a pharmaceutically acceptable amount of a copper chelator and an ACE inhibitor.
115. The method according to claim 114 wherein said ACE inhibitor is selected from the group consisting of captropril, lisinopril, and enalapril.
116. The method according to claim 114 wherein said copper chelator is a triene.
117. The method according to any of claims 114-116 wherein macrovascular and microvascular damage is lessened. pa a. *a a a.. COMS ID No: SMBI-00629208 Received by IP Australia: Time 14:23 Date 2004-02-20